Fabiola Loor Cedeño
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fabiola Loor Cedeño has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Carlos Ivan Soledispa Suárez
University of Guayaquil: Universidad de Guayaquil
1 shared publication - Luis Mariano de la Torre Fonseca
Hospital Comandante Manuel Fajardo, Cuba
1 shared publication - Mayra Elizabeth Briones Fajardo
University of Guayaquil: Universidad de Guayaquil
1 shared publication - Pablo Juan Salvadores
Hospital Álvaro Cunqueiro: Hospital Alvaro Cunqueiro
1 shared publication - Robert Alarcón Cedeño
Institute of Cardiovascular Health, Equador
1 shared publication - Stephanie Susana Alberca Bonilla
Servicio de Medicina, Instituto de Salud Cardiovascular (Isac-Med), Guayaquil, Ecuador
1 shared publication
Latest Publications
- Open Access
- 5 March 2024
- Published by Springer Nature in Research Square
Percutaneous Gastric Embolisation in Obese Patients: A Prospective Study of Mid-Term Outcomes
Introduction Obesity represents one of the most pressing public health challenges that needs to be solved globally, with serious health implications. Percutaneous gastric embolisation has emerged as a promising technique in the management of obesity. Objective This study aims to evaluate the relationship between endovascular procedure and weight loss in obese patients. In addition, to determine the complications related to percutaneous gastric embolisation in these patients. Design: Prospective longitudinal cohort study during the period from 1 January to 31 December 2022 and received treatment with percutaneous gastric embolisation Setting: This study includes patients admitted to the Haemodynamics Service of the Cardiovascular Health Institute during the year 2022. Participants: This study includes 15 patients diagnosed with grade III obesity who met the following criteria: patients ≥ 18 years with a diagnosis of obesity as determined by a body mass index greater than 30 kg/m2 and less than 40 kg/m 2, admitted between January to December 2022, and patients with a diagnosis of obesity with BMI > 40 kg/m2 with contraindication or refusal of bariatric. Main Outcome(s) and Measure(s): This is one of the largest studies in percutaneous gastric embolisation an obese population, while assessing the sustainability of weight loss outcomes. The main findings of the study can be summarised as follows: a) The procedure is safe without major complications, ulcers or gastric ischaemia, b) These technique achieves significant weight loss that is maintained over time. Results 86.7% were successful. Treated patients experienced significant weight loss when comparing baseline weight (101.2 ± 23.0 SE = 5.9) with weight at 6 months after the interventional procedure (91.5 ± 19.8, SE = 5.1) t(14) = 5.3, p < 0.001, d = 0.45. Especially males (106.7 ± 18.4, p = 0.01). No major vascular complications, gastric ulcer or ischaemia, or abdominal symptoms were documented in any of the patients included in the study. Only 6 patients (40%) presented with epigastralgia, 9 (60%) with nausea and 3 (20%) with vomiting. Conclusions Percutaneous gastric embolisation is an effective and safe procedure to reduce body mass index with a high success rate, well tolerated by obese patients, without major complications, whose results are maintained over time.
- 5 March 2024
- Published by Springer Nature in Research Square
Open AccessPercutaneous Gastric Embolisation in Obese Patients: A Prospective Study of Mid-Term Outcomes
Introduction Obesity represents one of the most pressing public health challenges that needs to be solved globally, with serious health implications. Percutaneous gastric embolisation has emerged as a promising technique in the management of obesity. Objective This study aims to evaluate the relationship between endovascular procedure and weight loss in obese patients. In addition, to determine the complications related to percutaneous gastric embolisation in these patients. Design: Prospective longitudinal cohort study during the period from 1 January to 31 December 2022 and received treatment with percutaneous gastric embolisation Setting: This study includes patients admitted to the Haemodynamics Service of the Cardiovascular Health Institute during the year 2022. Participants: This study includes 15 patients diagnosed with grade III obesity who met the following criteria: patients ≥ 18 years with a diagnosis of obesity as determined by a body mass index greater than 30 kg/m2 and less than 40 kg/m 2, admitted between January to December 2022, and patients with a diagnosis of obesity with BMI > 40 kg/m2 with contraindication or refusal of bariatric. Main Outcome(s) and Measure(s): This is one of the largest studies in percutaneous gastric embolisation an obese population, while assessing the sustainability of weight loss outcomes. The main findings of the study can be summarised as follows: a) The procedure is safe without major complications, ulcers or gastric ischaemia, b) These technique achieves significant weight loss that is maintained over time. Results 86.7% were successful. Treated patients experienced significant weight loss when comparing baseline weight (101.2 ± 23.0 SE = 5.9) with weight at 6 months after the interventional procedure (91.5 ± 19.8, SE = 5.1) t(14) = 5.3, p < 0.001, d = 0.45. Especially males (106.7 ± 18.4, p = 0.01). No major vascular complications, gastric ulcer or ischaemia, or abdominal symptoms were documented in any of the patients included in the study. Only 6 patients (40%) presented with epigastralgia, 9 (60%) with nausea and 3 (20%) with vomiting. Conclusions Percutaneous gastric embolisation is an effective and safe procedure to reduce body mass index with a high success rate, well tolerated by obese patients, without major complications, whose results are maintained over time.